TITLE

At Your Own RISK

AUTHOR(S)
Lemonick, Michael D.; Goldstein, Andrew; Park, Alice
PUB. DATE
April 2002
SOURCE
Time International (South Pacific Edition);4/22/2002, Issue 15, p46
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
Focuses on the risks associated with clinical trials in medicine. Debate about the safety regulations of the trials, which often involve desperately ill patients; Expectation that the number of trials will increase, and along with that, the number of deaths; Description of various scandals such as one involving Dr. Michael McGee's treatment of Cherlynn Mathias; Topic of medical ethics; Financial conflicts of interest.
ACCESSION #
6587464

 

Related Articles

  • The evolution of standards for experimental treatment or research. Slovenko, Ralph // Journal of Psychiatry & Law;Spring2005, Vol. 33 Issue 1, p129 

    Discusses the historical evolution of standards for experimental treatment or research involving human subjects. Key reason for the creation of standards; Debates on the universal standards for justifying human experiments at the Nuremberg tribunal; Basis of the U.S. Supreme Court in supporting...

  • Personal reflections on lessons learned from randomized trials involving newborn infants from 1951 to 1967. Silverman, William A. // Clinical Trials;2004, Vol. 1 Issue 2, p179 

    The article discusses personal reflections on lessons learned from randomized trials involving newborn infants from 1951 to 1967. This essay is being reprinted from the James Lind Library, a wonderful online cornucopia of historical information created to introduce people to the characteristics...

  • The Problem with Optimism in Clinical Trials. Jansen, Lynn A. // IRB: Ethics & Human Research;Jul/Aug2006, Vol. 28 Issue 4, p13 

    The author reflects on the phenomenon of "unrealistic optimism" in clinical research compromising informed consent. She argues that its implications for the ethics of clinical research have not been fully appreciated and the phenomenon may be more difficult to address than either the therapeutic...

  • No delayed disclosure for registration of clinical trials. Fleck, Fiona // Bulletin of the World Health Organization;Jun2006, Vol. 84 Issue 6, p430 

    The article reports that the World Health Organization has introduced disclosure rules for pharmaceutical companies and research institutions to make clinical trials more transparent and publicly accountable. They will have to submit 20 key details when they register clinical trials with human...

  • Human Subjects Research: HHS Takes Steps to Strengthen Protections, But Concerns Remain: GAO-01-775T.  // GAO Reports;5/23/2001, p1 

    At the federal level the Department of Health and Human Services (HHS) is seeking to better protect human subjects in biomedical research by enhancing the visibility of its human subjects protection activities, improving its monitoring of compliance with relevant regulations by institutions and...

  • They're Dying to Get In. Bjerklie, David // Time International (South Pacific Edition);4/22/2002, Issue 15, p55 

    Discusses the difficulty of being able to participate in clinical trials in medicine. Benefits of the trials, including substantial doctor-patient interaction; Idea that it is not just the terminally ill who benefit from the attention, but also medically neglected or poorly informed subjects...

  • Giving patients better access to trial information. Humphreys, Gary // Bulletin of the World Health Organization;Jun2006, Vol. 84 Issue 6, p429 

    The article focuses on the global clinical trials registry initiative launched by the World Health Organization. It is a Web-based search platform available to the public. Companies and research institutions would have to register the details of the clinical trials conducted by them. They will...

  • Could have been a contender. Iheanacho, Ike // BMJ: British Medical Journal (International Edition);6/7/2008, Vol. 336 Issue 7656, p1312 

    The author reflects on the ethics of publicity related to the results of clinical trials. He suggests that new medicines are not always placed in head to head comparisons with established medicines. He argues that this lack of comparison is the result of regulatory bodies in medicine and...

  • Patient power in randomised controlled trials.  // BMJ: British Medical Journal (International Edition);5/3/2003, Vol. 326 Issue 7396, p990 

    Reviews the website of the week. Designation of CERES as a useful resource for researchers seeking practical advice about writing patient information sheets to be used in clinical trials; Discussion about the ethics of clinical trials.

Share

Read the Article

Other Topics